Care of the Cirrhotic Patient

Clinics in Liver Disease

Volumn 13, Issue 2, 2009, Pages 331-340

  Grewal, Priya ^a   Martin, Paul ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Ascites; Cirrhosis; Complications; Encephalopathy; HCC

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; FUROSEMIDE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LACTULOSE; NORFLOXACIN; PNEUMOCOCCUS VACCINE; SPIRONOLACTONE; TIMOLOL;

ASCITES; BACTERIAL PERITONITIS; CANCER SCREENING; CLINICAL TRIAL; DRUG DOSE INCREASE; EARLY DIAGNOSIS; ESOPHAGUS HEMORRHAGE; ESOPHAGUS VARICES; HEPATIC ENCEPHALOPATHY; HEPATITIS A; HEPATITIS B; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFLUENZA; LIGATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORNING DOSAGE; PNEUMOCOCCAL INFECTION; PRIMARY PREVENTION; QUALITY OF LIFE; REVIEW; SCREENING TEST; SECONDARY PREVENTION; SINGLE DRUG DOSE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ASCITES; CARCINOMA, HEPATOCELLULAR; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PARACENTESIS; PERITONITIS; VARICOSE VEINS;

EID: 65149104641     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.02.006     Document Type: Review

References (75)

1. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112 (1997) 463-472
2. Groszmann R.J., Garcia-Tsao G., Bosch J., et al. Beta blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353 (2005) 2254-2261
3. D'Amico G., Pagliaro L., and Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 22 (1995) 332-354
4. D'Amico G., and Luca A. Natural history-clinical-haemodynamic correlations: prediction of the risk of bleeding. Baillieres Clin Gastroenterol 11 (1997) 243-256
5. D'Amico G., Garcia-Tsao G., and Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44 (2006) 217-231
6. de Franchis R. Evolving consensus in portal hypertension: report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 43 (2005) 167-176
7. Merli M., Nicolini G., Angeloni S., et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 38 (2003) 266-272
8. de Franchis R. Evaluation and follow-up of patients with cirrhosis and oesophageal varices. J Hepatol 38 (2003) 361-363
9. Eisen G.M., Eliakim R., Zaman A., et al. The accuracy of PillCam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: a prospective three-center pilot study. Endoscopy 38 (2006) 31-35
10. Lapalus M.G., Dumortier J., Fumex F., et al. Esophageal capsule endoscopy versus esophagogastroduodenoscopy for evaluating portal hypertension: a prospective comparative study of performance and tolerance. Endoscopy 38 (2006) 36-41
11. Frenette C., Kuldau J.G., Hillebrand D., et al. Comparison of esophageal pill endoscopy and conventional endoscopy for variceal screening. Hepatology 44 Suppl 1 (2006) 445A
12. D'Amico G., Pagliaro L., and Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 19 (1999) 475-505
13. North Italian Endoscopic Club. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. The North Italian Endoscopic Club for the study and treatment of Esophageal Varices. N Engl J Med 319 (1988) 983-989
14. Merkel C., Marin R., Angeli P., et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 127 (2004) 476-484
15. Imperiale T.F., and Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 33 (2001) 802-807
16. Lo G.H., Chen W.C., Chen M.H., et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 59 (2004) 333-338
17. Chen C.Y., Sheu M.Z., Tsai T.L., et al. Endoscopic variceal ligation with multiple band ligator for prophylaxis of first hemorrhage esophageal varices. Endoscopy 31 Suppl 1 (1999) 35A
18. Schepke M., Kleber G., Nurnberg D., et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 40 (2004) 65-72
19. Song H., Shin J.W., Kim H.I., et al. A prospective randomized trial between the prophylactic endoscopic variceal ligation and propranolol administration for prevention of first bleeding in cirrhotic patients with high-risk esophageal varices. J Hepatol 32 Suppl 2 (2000) 41A
20. Sarin S.K., Lamba G.S., Kumar M., et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 340 (1999) 988-993
21. de la Mora G., Farca-Belsaguy A.A., Uribe M., et al. Ligation vs propranolol for primary prophylaxis of variceal bleeding using multiple band ligator and objective measurements of treatment adequacy: preliminary results. Gastroenterology 118 (2000) 6511A
22. Lui H.F., Stanley A.J., Forrest E.H., et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 123 (2002) 735-744
23. Jutabha R., Jensen D.M., Martin P., et al. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 128 (2005) 870-881
24. Thuluvath P.J., Maheshwari A., Jagannath S., et al. A randomized controlled trial of beta-blockers versus endoscopic band ligation for primary prophylaxis: a large sample size is required to show a difference in bleeding rates. Dig Dis Sci 50 (2005) 407-410
25. De B.K., Ghoshal U.C., Das T., et al. Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial. J Gastroenterol Hepatol 14 (1999) 220-224
26. Drastich P., Lata J., Petrtyl J., et al. Endoscopic variceal band ligation in comparison with propranolol in prophylaxis of first variceal bleeding in patients with liver cirrhosis. J Hepatol 42 (2005) 202A
27. Lay C.S., Tsai Y.T., Lee F.Y., et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 21 (2006) 413-419
28. Psilopoulos D., Galanis P., Goulas S., et al. Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial. Eur J Gastroenterol Hepatol 17 (2005) 1111-1117
29. Abdelfattah M.H., Rashed M.A., Elfakhry A.A., et al. Endoscopic variceal ligation versus pharmacological treatment for primary prophylaxis of variceal bleeding: a randomized study. J Hepatol 44 Suppl 2 (2006) 83A
30. Gheorghe C., Gheorghe L., Vadan R., et al. Prophylactic banding ligation of high-risk esophageal varices in patients on the waiting list for liver transplantation: an interim analysis. J Hepatol 36 Suppl 1 (2002) 38A
31. Norberto L., Polese L., Cillo U., et al. A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl 13 (2007) 1272-1278
32. Triantos C., Vlachogiannakos J., Armonis A., et al. Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers: a randomized trial of ligation. Aliment Pharmacol Ther 21 (2005) 1435-1443
33. Yoshida H., Mamada Y., Taniai N., et al. A randomized control trial of bi-monthly versus bi-weekly endoscopic variceal ligation of esophageal varices. Am J Gastroenterol 100 (2005) 2005-2009
34. El-Serag, Marrero J., Rudolph L., et al. Diagnosis and treatment of Hepatocellular Carcinoma. Gastroenterology 134 (2008) 1752-1763
35. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
36. Zhang B.H., Yang B.H., and Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004) 417-422
37. Trevisani F., De N.S., Rapaccini G., et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 97 (2002) 734-744
38. Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48 (2001) 251-259
39. Bayati N., Silverman A.L., and Gordon S.C. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 93 (1998) 2452-2456
40. Saab S., Ly D., Nieto J., et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 9 (2003) 672-681
41. Choi D., Kim S.H., Lim J.H., et al. Detection of hepatocellular carcinoma: combined T2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography. J Comput Assist Tomogr 25 (2001) 777-785
42. Arguedas M.R., Chen V.K., Eloubeidi M.A., et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 98 (2003) 679-690
43. Marrero J.A., Hussain H.K., Nghiem H.V., et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially enhancing liver mass. Liver Transpl 11 (2005) 281-289
44. D'Amico G., Morabito A., Pagliaro L., et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 31 (1986) 468-475
45. Runyon B.A., Montano A.A., Akriviadis E.A., et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 117 (1992) 215-220
46. Runyon B.A. Management of the adult patient with ascites due to cirrhosis. Hepatology 39 (2004) 841-856
47. Runyon B.A. Care of patients with ascites. N Engl J Med 330 (1994) 337-342
48. Tito L., Rimola A., Gines P., et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 8 (1988) 27-31
49. Gines P., Rimola A., Planas R., et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 12 (1990) 716-724
50. Llach J., Rimola A., Navasa M., et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 16 (1992) 724-727
51. Guarner C., Sola R., Soriano G., et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 117 (1999) 495-499
52. Fernandez J., Navasa M., Planas R., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133 (2007) 818-824
53. Terg R., Fassio E., Guevara M., et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 48 (2008) 774-779
54. Riordan S.M., and Williams R. Treatment of Hepatic encephalopathy. N Engl J Med 337 (1997) 473-479
55. Bajaj J., Hafeezullah M., Franco J., et al. Inhibitory Control Test for the Diagnosis of Minimal Hepatic Encephalopathy. Gastroenterology 135 5 (2008) 1591-1600 e1
56. Wein C., Koch H., Popp B., et al. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 39 (2004) 739-745
57. Romero-Gomez M., Boza F., Garcia-Valdecasas M.S., et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 96 (2001) 2718-2723
58. Amodio P., Del Piccolo F., Marchetti P., et al. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 29 (1999) 1662-1667
59. Prasad S., Dhiman R., Duseja A., et al. Lactulose improves cognitive functions and health- related quality of patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45 (2007) 549-559
60. Bajaj J.S., Saejan K., Christensen K.M., et al. Probiotic yogurt for treatment of minimal hepatic encephalopathy. Am J Gastroenterol 103 7 (2008) 1707-1715
61. Navasa M., Rimola A., and Rodé s J. Bacterial infections in liver disease. Semin Liver Dis 17 (1997) 323-333
62. Duchini A., Viernes M.E., Nyberg L.M., et al. Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med 160 (2000) 113-115
63. Keeffe E.B. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?. Am J Gastroenterol 90 (1995) 201-205
64. Yao G. Clinical spectrum and natural history of viral hepatitis in a 1988 Shanghai epidemic. In: Hollinger F.B., Lemon S.M., and Margolis H. (Eds). Viral hepatitis and liver disease (1991), Lippincott Williams & Wilkins, Baltimore (MD) 76-78
65. Fukumoto Y., Okita K., Konishi T., et al. Hepatitis A infection in chronic carriers of hepatitis B virus. In: Sung J.-L., and Chen D.-S. (Eds). Viral hepatitis and hepatocellular carcinoma (1990), Excerpta Medica, Amsterdam 43-48
66. Papachristou A.A., Dumas A.S., and Katsouyannopoulos V.C. Dissociation of alanine aminotransferase values in acute hepatitis A patients with and without past experience to the hepatitis B virus. Epidemiol Infect 106 (1991) 397-402
67. Vento S., Garofano T., Renzini C., et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 338 (1998) 286-290
68. Fé ray C., Gigou M., Samuel D., et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 104 (1993) 549-555
69. McCashland T.M., Preheim L.C., and Gentry M.J. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 181 (2000) 757-760
70. Arguedas M.R., McGuire B.M., and Fallon M.B. Implementation of vaccination in patients with cirrhosis. Dig Dis Sci 47 (2002) 384-387
71. Saab S., Lee C., Shpaner A., et al. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat 12 (2005) 101-105
72. Arguedas M.R., Johnson A., Eloubeidi M.A., et al. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 34 (2001) 28-31
73. Smallwood G.A., Coloura C.T., Martinez E., et al. Can patients awaiting liver transplantation elicit an immune response to the hepatitis A vaccine?. Transplant Proc 34 (2002) 3289-3290
74. Dominguez M., Barcena R., Garcia M., et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 6 (2000) 440-442
75. Arslan M., Wiesner R.H., Sievers C., et al. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 7 (2001) 314-320